Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Renal Drug Excretion: Overview01:15

Renal Drug Excretion: Overview

As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

The prevalence of the common LCHAD c.1528G>C p.(Glu510Gln) pathogenic variant in women diagnosed with acute fatty liver of pregnancy.

Obstetric medicine·2026
Same author

Delayed-type hypersensitivity to low-molecular-weight heparin and cross-reactivity to fondaparinux and danaparoid in a twin pregnancy.

Obstetric medicine·2026
Same author

Renal angiomyolipoma in pregnancy - A review.

Obstetric medicine·2026
Same author

Hypocholesterolaemia as an early feature of presumed acute fatty liver of pregnancy.

Obstetric medicine·2026
Same author

Darbepoetin therapy for anaemia and orthostatic presyncope and palpitations in a woman with beta-thalassemia minor and possible postural orthostatic tachycardia syndrome.

Obstetric medicine·2026
Same author

Reduction in insulin requirements in second trimester in a woman with type 2 diabetes mellitus associated with anti-insulin antibodies: A case of exogenous insulin autoimmune syndrome?

Obstetric medicine·2026
Same journal

Anti-GAD antibody-associated epilepsy in pregnancy.

Obstetric medicine·2026
Same journal

Postpartum therapeutic anticoagulation and uterine wall haematoma: A case report.

Obstetric medicine·2026
Same journal

Renal tubular acidosis (RTA) complicated pregnancies: A tertiary centre experience.

Obstetric medicine·2026
Same journal

A woman with homozygous familial hypercholesterolaemia requiring lipoprotein apheresis and coronary artery bypass graft in pregnancy.

Obstetric medicine·2026
Same journal

Refractory hypokalemic metabolic alkalosis in pregnancy: Interplay of hyperemesis gravidarum and primary hyperparathyroidism.

Obstetric medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 30, 2026

In Utero Intra-cardiac Tomato-lectin Injections on Mouse Embryos to Gauge Renal Blood Flow
10:25

In Utero Intra-cardiac Tomato-lectin Injections on Mouse Embryos to Gauge Renal Blood Flow

Published on: February 4, 2015

Eplerenone in pregnancy.

Adam Morton1,2

  • 1Department of Obstetric Medicine, Mater Hospital Brisbane, South Brisbane, Queensland, Australia.

Obstetric Medicine
|June 29, 2026
PubMed
Summary
This summary is machine-generated.

Eplerenone, a mineralocorticoid receptor antagonist, shows potential therapeutic benefits during pregnancy. This review explores its efficacy and safety for various pregnancy-related conditions.

Keywords:
Eplerenonecardiomyopathyhypertensionpregnancyprimary aldosteronism

Related Experiment Videos

Last Updated: Jun 30, 2026

In Utero Intra-cardiac Tomato-lectin Injections on Mouse Embryos to Gauge Renal Blood Flow
10:25

In Utero Intra-cardiac Tomato-lectin Injections on Mouse Embryos to Gauge Renal Blood Flow

Published on: February 4, 2015

Area of Science:

  • Pharmacology
  • Obstetrics and Gynecology
  • Nephrology

Background:

  • Eplerenone is a selective mineralocorticoid receptor antagonist with low androgen receptor affinity.
  • Mineralocorticoid receptor antagonists are established treatments for conditions like resistant hypertension, cardiac dysfunction, and kidney diseases.
  • Limited data exists on eplerenone use in pregnancy.

Purpose of the Study:

  • To review existing literature on eplerenone use in pregnancy.
  • To discuss potential indications for eplerenone during gestation.
  • To present case studies of eplerenone administration in pregnant patients.

Main Methods:

  • Literature review of eplerenone in pregnancy.
  • Case series analysis of five pregnant patients using eplerenone.
  • Discussion of pharmacological properties and potential applications.

Main Results:

  • Five cases of eplerenone use in pregnancy were analyzed.
  • Previous literature on eplerenone in pregnancy was systematically reviewed.
  • Potential therapeutic roles for eplerenone in pregnancy were identified.

Conclusions:

  • Eplerenone may offer a safe and effective treatment option for specific conditions during pregnancy.
  • Further research is warranted to establish definitive guidelines for eplerenone use in pregnant populations.
  • The review highlights the need for careful consideration of mineralocorticoid receptor antagonism in obstetric care.